| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8926090 | Medicina Universitaria | 2016 | 8 Pages |
Abstract
Purine analogues remain the first line of treatment. However, interferon and rituximab are a valid option, if the ideal treatment is unavailable. New discoveries in the pathophysiology of HCL have brought the creation of pharmaceuticals with distinct therapeutic targets. These pharmaceuticals are currently undergoing testing.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
M.A. Garza-Ledezma, C.A. Tellez-Hinojosa, E.E. González-López, D. Gómez-Almaguer,